Gilgamesh Pharmaceuticals

0 reviews

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company dedicated to transforming mental health treatment by developing innovative, rapid-acting, and durable therapies. Founded in 2019 and headquartered in New York, the company focuses on creating novel chemical entities (NCEs) that address the root causes of psychiatric disorders, moving beyond traditional symptom management. Key Features and Functionality: - NMDAR Antagonists: Gilgamesh is developing orally bioavailable, rapid-acting N-methyl-D-aspartate receptor (NMDAR) antagonists with reduced dissociative effects, aiming to provide effective treatment options for depression. - Neuroplastogens: The company is working on non-hallucinogenic, rapid-acting neuroplastogens that are orally bioavailable, targeting depression and anxiety disorders. - Safer Ibogaine Analogs: Gilgamesh is developing ibogaine analogs with improved cardiac safety profiles, offering rapid and sustained efficacy for opioid use disorder and other indications. Primary Value and Solutions: Gilgamesh Pharmaceuticals aims to revolutionize mental health care by shifting the treatment paradigm from symptom management to addressing the fundamental drivers of psychiatric diseases. By leveraging advanced medicinal chemistry and an AI-powered discovery platform, the company accelerates the creation of precision psychiatric therapies. Their innovative approach offers patients rapid-acting and long-lasting treatment options, potentially improving outcomes for conditions such as depression, anxiety, and substance use disorders.